news
Gilead Sciences to acquire Immunomedics for $21 billion
Gilead is set to acquire Immunomedics for approximately $21 billion, with the transaction anticipated to close in the fourth quarter of 2020.
List view / Grid view
Big Pharma
Filter the results
news
British pharma industry responds to new Brexit guidance from MHRA
The ABPI has responded to new guidance, intended to prepare pharma companies for the end of the Brexit transition period, from the MHRA.
news
Nestlé Health Science to acquire Aimmune Therapeutics for $2.6 billion
Nestlé Health Science will acquire Aimmune Therapeutics for a total value of $2.6 billion, extending the former's food allergy portfolio.
news
First patients dosed in GSK’s Phase III meningitis vaccine trial
The trial will assess the safety, tolerability and immunogenicity of the five-in-one MenABCWY vaccine in participants aged 10 to 25.
article
European Pharmaceutical Review Issue 4 2020
Within this issue find articles on the complexities of sterility assurance, how to detect and eliminate the risk of NDMA contamination and the findings from a study involving a novel formulation of cannabinoids that has been developed to treat glioblastoma. Also included are articles on the opportunities blockchain provides for…
news
Sanofi to acquire Principa Biopharma for $3.68 billion
Sanofi is set to acquire Principia Biopharma Inc. for a total aggregate equity value of $3.68 billion, at $100 per share.
news
AstraZeneca to supply Europe with up to 400 million doses of COVID-19 vaccine
An agreement between AstraZeneca and the European Commission means the company will supply up to 400 million doses of its AZD1222 COVID-19 vaccine.
news
Bayer to acquire KaNDy Therapeutics with $425 million upfront payment
Bayer will acquire KaNDy Therapeutics Ltd for an upfront cost of $425 million to expand its drug development pipeline in women’s healthcare.
news
Activity at Kodak Pharmaceuticals regarding US government loan to be reviewed
After "allegations of wrongdoing" were connected to Eastman Kodak Company following a $765 million loan from the US government, a review has been announced.
news
Licensing agreement deals decline in rare diseases space, says report
New research has shown that complex collaborations and partnerships are increasing, while licensing agreements are decreasing in the rare disease space.
webinar
Delivering value: how LIMS can enable data integrity in pharma manufacturing
4 August 2020 | By Thermo Fisher Scientific
Find out more about industry issues, solutions, trends and how LIMS can enable laboratories to accelerate science and drive productivity, while ensuring regulatory compliance in our upcoming webinar.
article
Top 10 biopharma workplaces in the US
A Fortune report reveals the best 10 places to work in the US biopharmaceutical industry.
news
Pfizer and BioNTech to supply up to 600 million doses of COVID-19 vaccine to US
An agreement between the US government and Pfizer and BioNTech will have the companies produce an initial 100 million doses of their COVID-19 vaccine candidate, with the potential for 500 million more.
article
Is global COVID-19 expertise accessible enough?
Does expert knowledge on COVID-19 need to be more accessible across the globe? This article explores this issue and addresses how greater accessibility could help fight the pandemic in emerging countries.
news
Johnson & Johnson to start COVID-19 vaccine trials next week
The company will start enrolment to the Ad26.COV2-S vaccine trial next week, it anticipates initial results in September.